Wechselwirkungen · Vizarsin
Vizarsin 25 mg orodispersible tablets Vizarsin 50 mg orodispersible tablets Vizarsin 100 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 19
HOS-210917 · Präparat HOS-154603
When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC). In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC, Cmax, tmax, elimination rate constant, or subsequent half-life of sildenafil or its principal circulating metabolite. Cimetidine (800 mg), a cytochrome P450 inhibitor and non-specific CYP3A4 inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) azithromycin (HOS-088112) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-02-24T16:29:00Z · SHA-256 2f808d91fd284718f9fd3477080213020dbb8a472917304bcbc8075d93a4c6f6 · Passage af0bf6ded38ff0767d107642a9116c14aa01848c1cd8bef75028af2e9f96ad84 · Zeichen 2056–2726 im Abschnitt